Open AccessImpact of newer direct-acting antiviral drugs based on quality-adjusted life years: A prospective pharmacoeconomic study in hepatitis C patients
Author(s) -
Bhavya H Vyas,
Nishita H. Darji,
Devang Rana,
Kaushal Y Vyas,
Supriya D. Malhotra
Publication year - 2021
Publication title -
perspectives in clinical research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.649
H-Index - 8
eISSN - 2229-5488
pISSN - 2229-3485
DOI - 10.4103/picr.picr_123_19
Subject(s) - medicine , sofosbuvir , pharmacoeconomics , quality of life (healthcare) , cost effectiveness , ribavirin , regimen , hepatitis c , ledipasvir , prospective cohort study , indirect costs , pharmacotherapy , intensive care medicine , hepatitis c virus , virology , virus , business , risk analysis (engineering) , nursing , accounting
The Indian government is dispensing newer direct-acting antiviral (DAA) drugs, which may have impact on hepatitis C virus (HCV) patients' quality of life (QoL).